Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nebius Group NV (NBIS) vs Novartis AG (NVS) Price & Performance

Nebius Group NVTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Nebius Group NV vs Novartis AG — how do they compare? Nebius Group NV trades at $229.43 (market cap $49.06B), while Novartis AG trades at $152.32 (market cap $295.37B). The key difference: Novartis AG is far larger — about 6× Nebius Group NV's market cap, and Novartis AG pays a 3.07% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.

NBISNVS
Market Cap
$49.06B$295.37B
Sector
TechnologyHealth
52-Week High
$286.69$168.62
52-Week Low
$64.06$119.31
Enterprise Value
$49.26B$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nebius Group NV

No Aura AI signal available yet.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS